{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:33:33Z","timestamp":1792100013281,"version":"4.4.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-009200"],"award-info":[{"award-number":["MJFF-009200"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-009200"],"award-info":[{"award-number":["MJFF-009200"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1181864"],"award-info":[{"award-number":["APP1181864"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1181864"],"award-info":[{"award-number":["APP1181864"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Misfolded wild-type superoxide dismutase 1 (disSOD1) protein is implicated in the death of substantia nigra (SN) dopamine neurons in Parkinson disease. Regionally reduced copper availability, and subsequent reduced copper binding to SOD1, is a key factor driving the development of this pathology, suggesting brain copper supplementation may constitute an effective means of preventing its formation. We evaluated whether the blood-brain-barrier-permeable copper delivery drug, CuATSM, attenuated the misfolding and deposition of wild-type disSOD1 and associated neuron death in a novel mouse model that expresses this pathology. These factors were profiled using proteomic and elemental mass spectrometry, together with biochemical and histological workflows. We demonstrated copper supplementation corrects altered post-translational modifications on soluble SOD1 and improves the enzymatic activity of the protein in the brains of these animals. These changes were associated with a significant reduction in disSOD1 pathology and preservation of dopamine neurons in the SN, which were highly correlated with tissue copper levels. Our data position wild-type disSOD1 pathology as a novel drug target for Parkinson disease and suggest that brain copper supplementation may constitute an effective means of slowing SN dopamine neuron death in this disorder.<\/jats:p>","DOI":"10.1186\/s40478-025-02048-2","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T03:03:59Z","timestamp":1750820639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Copper supplementation mitigates Parkinson-like wild-type SOD1 pathology and nigrostriatal degeneration in a novel mouse model"],"prefix":"10.1186","volume":"13","author":[{"given":"Benjamin D.","family":"Rowlands","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin G.","family":"Trist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Karozis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Harwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Rosolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Cottam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freyja","family":"Persson-Carboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne A.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Gotsbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr H.","family":"Abdeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Codd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay L.","family":"Double","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"2048_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"VL Feigin","year":"2017","unstructured":"Feigin VL et al (2017) Global, regional, and National burden of neurological disorders during 1990\u20132015: a systematic analysis for the global burden of disease study 2015. Lancet Neurol 16:877\u2013897","journal-title":"Lancet Neurol"},{"key":"2048_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Collaborators GPsD (2018) Global, regional, and National burden of parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 17:939\u2013953","journal-title":"Lancet Neurol"},{"key":"2048_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR (2018) The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 8:S3\u2013S8","journal-title":"J Parkinsons Dis"},{"key":"2048_CR4","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397:2284\u20132303","journal-title":"Lancet"},{"key":"2048_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU et al (2024) A biological classification of parkinson\u2019s disease: the synneurge research diagnostic criteria. Lancet Neurol 23:191\u2013204","journal-title":"Lancet Neurol"},{"key":"2048_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(24)00094-1","volume":"403","author":"Lancet","year":"2024","unstructured":"Lancet (2024) What next in parkinson\u2019s disease? Lancet 403:219","journal-title":"Lancet"},{"key":"2048_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","volume":"403","author":"T Foltynie","year":"2024","unstructured":"Foltynie T et al (2024) Medical, surgical, and physical treatments for parkinson\u2019s disease. Lancet 403:305\u2013324","journal-title":"Lancet"},{"key":"2048_CR8","doi-asserted-by":"crossref","unstructured":"Mahlknecht P, Poewe W (2024) Pharmacotherapy for Disease Modification in Early Parkinson\u2019s Disease: How Early Should We Be? J Parkinsons Dis","DOI":"10.3233\/JPD-230354"},{"key":"2048_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00401-017-1726-6","volume":"134","author":"BG Trist","year":"2017","unstructured":"Trist BG et al (2017) Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in parkinson\u2019s disease brain. Acta Neuropathol 134:113\u2013127","journal-title":"Acta Neuropathol"},{"key":"2048_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00401-017-1779-6","volume":"135","author":"BG Trist","year":"2018","unstructured":"Trist BG et al (2018) Accumulation of dysfunctional SOD1 protein in parkinson\u2019s disease is not associated with mutations in the SOD1 gene. Acta Neuropathol 135:155\u2013156","journal-title":"Acta Neuropathol"},{"key":"2048_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen DR et al (1993) Mutations in cu\/zn Superoxide-dismutase gene are associated with Familial amyotrophic lateral sclerosis. Nature 362:59\u201362","journal-title":"Nature"},{"key":"2048_CR12","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.neurobiolaging.2013.09.034","volume":"35","author":"KM Davies","year":"2014","unstructured":"Davies KM et al (2014) Copper pathology in vulnerable brain regions in parkinson\u2019s disease. Neurobiol Aging 35:858\u2013866","journal-title":"Neurobiol Aging"},{"key":"2048_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.abb.2010.08.014","volume":"503","author":"SV Seetharaman","year":"2010","unstructured":"Seetharaman SV, Taylor AB, Holloway S, Hart PJ (2010) Structures of mouse SOD1 and human\/mouse SOD1 chimeras. Arch Biochem Biophys 503:183\u2013190","journal-title":"Arch Biochem Biophys"},{"key":"2048_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1039\/C2MT20151H","volume":"5","author":"KM Davies","year":"2013","unstructured":"Davies KM et al (2013) Localization of copper and copper transporters in the human brain. Metallomics 5:43\u201351","journal-title":"Metallomics"},{"key":"2048_CR15","doi-asserted-by":"crossref","unstructured":"Abdeen AH et al (2025) Parkinson-like wild-type superoxide dismutase 1 pathology induces nigral dopamine neuron degeneration in a novel murine model. Acta Neuropathol","DOI":"10.1007\/s00401-025-02859-6"},{"key":"2048_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2016.01.020","volume":"89","author":"JR Williams","year":"2016","unstructured":"Williams JR et al (2016) Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD. Neurobiol Dis 89:1\u20139","journal-title":"Neurobiol Dis"},{"key":"2048_CR17","doi-asserted-by":"publisher","first-page":"8021","DOI":"10.1523\/JNEUROSCI.4196-13.2014","volume":"34","author":"B Roberts","year":"2014","unstructured":"Roberts B et al (2014) Oral treatment with CuII(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a Transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 34:8021\u20138031","journal-title":"J Neurosci"},{"key":"2048_CR18","volume-title":"Condensation products of some a-diketones, especially 3-methyl-2-cyclopentonone with Thiosemicarbazide","author":"GR Gummerus","year":"1966","unstructured":"Gummerus GR (1966) Condensation products of some a-diketones, especially 3-methyl-2-cyclopentonone with Thiosemicarbazide. Societas Scientiarum Fennica, Helsinki"},{"key":"2048_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s007750100291","volume":"7","author":"JL Dearling","year":"2002","unstructured":"Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ (2002) Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 7:249\u2013259","journal-title":"J Biol Inorg Chem"},{"key":"2048_CR20","unstructured":"NHMRC. Australian code for the care and use of animals for scientific purposes (2013)"},{"key":"2048_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neurobiolaging.2024.01.003","volume":"136","author":"E Suryana","year":"2024","unstructured":"Suryana E, Rowlands BD, Bishop DP, Finkelstein DI, Double KL (2024) Empirically derived formulae for calculation of age- and region-related levels of iron, copper and zinc in the adult C57BL\/6 mouse brain. Neurobiol Aging 136:34\u201343","journal-title":"Neurobiol Aging"},{"key":"2048_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.bbi.2020.04.015","volume":"88","author":"J Scarborough","year":"2020","unstructured":"Scarborough J et al (2020) Preclinical validation of the micropipette-guided drug administration (MDA) method in the maternal immune activation model of neurodevelopmental disorders. Brain Behav Immun 88:461\u2013470","journal-title":"Brain Behav Immun"},{"key":"2048_CR23","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1093\/brain\/awac165","volume":"145","author":"BG Trist","year":"2022","unstructured":"Trist BG et al (2022) Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. Brain 145:3108\u20133130","journal-title":"Brain"},{"key":"2048_CR24","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1021\/acs.jproteome.6b00464","volume":"15","author":"EC Keilhauer","year":"2016","unstructured":"Keilhauer EC, Geyer PE, Mann M (2016) HCD fragmentation of glycated peptides. J Proteome Res 15:2881\u20132890","journal-title":"J Proteome Res"},{"key":"2048_CR25","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1039\/C7MT00244K","volume":"9","author":"S Genoud","year":"2017","unstructured":"Genoud S et al (2017) Subcellular compartmentalisation of copper, iron, manganese, and zinc in the parkinson\u2019s disease brain. Metallomics 9:1447\u20131455","journal-title":"Metallomics"},{"key":"2048_CR26","doi-asserted-by":"publisher","first-page":"100316","DOI":"10.1016\/j.crmeth.2022.100316","volume":"2","author":"AM Ghoddousi","year":"2022","unstructured":"Ghoddousi AM, Magalong R, Kamitakahara VM, A.K., Levitt P (2022) SCAMPR, a single-cell automated multiplex pipeline for RNA quantification and Spatial mapping. Cell Rep Methods 2:100316","journal-title":"Cell Rep Methods"},{"key":"2048_CR27","doi-asserted-by":"crossref","unstructured":"Han S, Phasouk K, Zhu J, Fong Y (2023) Optimizing deep Learning-Based segmentation of densely packed cells using cell surface markers. Res Sq","DOI":"10.21203\/rs.3.rs-3307496\/v1"},{"key":"2048_CR28","doi-asserted-by":"crossref","unstructured":"Watson C, Paxinos G, Kayalioglu G (2009) Atlas of the mouse spinal cord. In: Watson C, Paxinos G, Kayalioglu G (eds) The spinal cord. Academic, pp 308\u2013379","DOI":"10.1016\/B978-0-12-374247-6.50020-1"},{"key":"2048_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fnagi.2016.00012","volume":"8","author":"VW Tung","year":"2016","unstructured":"Tung VW, Burton TJ, Quail SL, Mathews MA, Camp AJ (2016) Motor performance is impaired following vestibular stimulation in ageing mice. Front Aging Neurosci 8:12","journal-title":"Front Aging Neurosci"},{"key":"2048_CR30","doi-asserted-by":"publisher","first-page":"42292","DOI":"10.1038\/srep42292","volume":"13","author":"J Hilton","year":"2017","unstructured":"Hilton J et al (2017) CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci Rep 13:42292","journal-title":"Sci Rep"},{"key":"2048_CR31","doi-asserted-by":"publisher","first-page":"19392","DOI":"10.1038\/s41598-021-98317-w","volume":"11","author":"JS Lum","year":"2021","unstructured":"Lum JS et al (2021) CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1(G93A) mice with a C57BL\/6 background. Sci Rep 11:19392","journal-title":"Sci Rep"},{"key":"2048_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fnagi.2013.00009","volume":"5","author":"R Dringen","year":"2013","unstructured":"Dringen R, Scheiber IF, Mercer JF (2013) Copper metabolism of astrocytes. Front Aging Neurosci 5:9","journal-title":"Front Aging Neurosci"},{"key":"2048_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/hmg\/ddq463","volume":"20","author":"L Wang","year":"2011","unstructured":"Wang L, Gutmann DH, Roos RP (2011) Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R Transgenic mice. Hum Mol Genet 20:286\u2013293","journal-title":"Hum Mol Genet"},{"key":"2048_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00401-011-0805-3","volume":"121","author":"K Forsberg","year":"2011","unstructured":"Forsberg K, Andersen PM, Marklund SL, Brannstrom T (2011) Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis. Acta Neuropathol 121:623\u2013634","journal-title":"Acta Neuropathol"},{"key":"2048_CR35","doi-asserted-by":"publisher","first-page":"15699","DOI":"10.1074\/jbc.M112.425066","volume":"288","author":"M Basso","year":"2013","unstructured":"Basso M et al (2013) Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis. J Biol Chem 288:15699\u201315711","journal-title":"J Biol Chem"},{"key":"2048_CR36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.nurt.2010.05.012","volume":"7","author":"MR Vargas","year":"2010","unstructured":"Vargas MR, Johnson JA (2010) Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurotherapeutics 7:471\u2013481","journal-title":"Neurotherapeutics"},{"key":"2048_CR37","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.redox.2014.03.005","volume":"2","author":"D Martins","year":"2014","unstructured":"Martins D, English AM (2014) SOD1 oxidation and formation of soluble aggregates in yeast: relevance to sporadic ALS development. Redox Biol 2:632\u2013639","journal-title":"Redox Biol"},{"key":"2048_CR38","doi-asserted-by":"publisher","first-page":"166835","DOI":"10.1016\/j.bbadis.2023.166835","volume":"1869","author":"JR Monteiro Neto","year":"2023","unstructured":"Monteiro Neto JR et al (2023) Glycation modulates superoxide dismutase 1 aggregation and toxicity in models of sporadic amyotrophic lateral sclerosis. Biochim Biophys Acta Mol Basis Dis 1869:166835","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2048_CR39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41581-019-0129-4","volume":"15","author":"C Reily","year":"2019","unstructured":"Reily C, Stewart TJ, Renfrow MB, Novak J (2019) Glycosylation in health and disease. Nat Rev Nephrol 15:346\u2013366","journal-title":"Nat Rev Nephrol"},{"key":"2048_CR40","doi-asserted-by":"publisher","first-page":"9215","DOI":"10.1002\/anie.202000451","volume":"60","author":"BG Trist","year":"2021","unstructured":"Trist BG, Hilton JB, Hare DJ, Crouch PJ, Double KL (2021) Superoxide dismutase 1 in health and disease: how a frontline antioxidant becomes neurotoxic. Angew Chem Int Ed 60:9215\u20139246","journal-title":"Angew Chem Int Ed"},{"key":"2048_CR41","doi-asserted-by":"crossref","unstructured":"Banks CJ, Andersen JL (2019) Mechanisms of SOD1 regulation by post-translational modifications. Redox Biol 26","DOI":"10.1016\/j.redox.2019.101270"},{"key":"2048_CR42","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jmb.2012.04.016","volume":"421","author":"VK Mulligan","year":"2012","unstructured":"Mulligan VK et al (2012) Early steps in oxidation-induced SOD1 misfolding: implications for non-amyloid protein aggregation in Familial ALS. J Mol Biol 421:631\u2013652","journal-title":"J Mol Biol"},{"key":"2048_CR43","doi-asserted-by":"publisher","first-page":"101270","DOI":"10.1016\/j.redox.2019.101270","volume":"26","author":"C Banks","year":"2019","unstructured":"Banks C, Andersen J (2019) Mechanisms of SOD1 regulation by post-translational modifications. Redox Biol 26:101270","journal-title":"Redox Biol"},{"key":"2048_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fmolb.2016.00055","volume":"3","author":"I Sirangelo","year":"2016","unstructured":"Sirangelo I, Vella FM, Irace G, Manco G, Iannuzzi C (2016) Glycation in demetalated superoxide dismutase 1 prevents amyloid aggregation and produces cytotoxic ages adducts. Front Mol Biosci 3:55","journal-title":"Front Mol Biosci"},{"issue":"5","key":"2048_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ndt\/11.supp5.34","volume":"11","author":"J Fujii","year":"1996","unstructured":"Fujii J, Myint T, Okado A, Kaneto H, Taniguchi N (1996) Oxidative stress caused by glycation of Cu,Zn-superoxide dismutase and its effects on intracellular components. Nephrol Dial Transpl 11(5):34\u201340","journal-title":"Nephrol Dial Transpl"},{"key":"2048_CR46","doi-asserted-by":"publisher","first-page":"20578","DOI":"10.18632\/oncotarget.3987","volume":"6","author":"C Lin","year":"2015","unstructured":"Lin C et al (2015) Acetylation at lysine 71 inactivates superoxide dismutase 1 and sensitizes cancer cells to genotoxic agents. Oncotarget 6:20578","journal-title":"Oncotarget"},{"key":"2048_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bbrc.2013.10.033","volume":"441","author":"ZF Lin","year":"2013","unstructured":"Lin ZF et al (2013) SIRT5 desuccinylates and activates SOD1 to eliminate ROS. Biochem Biophys Res Commun 441:191\u2013195","journal-title":"Biochem Biophys Res Commun"},{"key":"2048_CR48","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.celrep.2013.07.024","volume":"4","author":"BT Weinert","year":"2013","unstructured":"Weinert BT et al (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4:842\u2013851","journal-title":"Cell Rep"},{"key":"2048_CR49","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1038\/ncomms4446","volume":"5","author":"CK Tsang","year":"2014","unstructured":"Tsang CK, Liu Y, Thomas J, Zhang Y, Zheng XF (2014) Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance. Nat Commun 5:3446","journal-title":"Nat Commun"},{"key":"2048_CR50","doi-asserted-by":"publisher","first-page":"15897","DOI":"10.1021\/ja407801x","volume":"135","author":"Y Shi","year":"2013","unstructured":"Shi Y et al (2013) Deamidation of asparagine to aspartate destabilizes cu, Zn superoxide dismutase, accelerates fibrillization, and mirrors ALS-linked mutations. J Am Chem Soc 135:15897\u201315908","journal-title":"J Am Chem Soc"},{"key":"2048_CR51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0022-510X(99)00300-7","volume":"173","author":"A Stieber","year":"2000","unstructured":"Stieber A, Gonatas JO, Gonatas NK (2000) Aggregation of ubiquitin and a mutant ALS-linked SOD1 protein correlate with disease progression and fragmentation of the golgi apparatus. J Neurol Sci 173:53\u201362","journal-title":"J Neurol Sci"},{"key":"2048_CR52","doi-asserted-by":"publisher","first-page":"33325","DOI":"10.1074\/jbc.M603489200","volume":"281","author":"M Basso","year":"2006","unstructured":"Basso M et al (2006) Insoluble mutant SOD1 is partly oligoubiquitinated in amyotrophic lateral sclerosis mice. J Biol Chem 281:33325\u201333335","journal-title":"J Biol Chem"},{"key":"2048_CR53","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.neulet.2012.04.018","volume":"516","author":"X Shan","year":"2012","unstructured":"Shan X, Vocadlo DJ, Krieger C (2012) Reduced protein O-glycosylation in the nervous system of the mutant SOD1 Transgenic mouse model of amyotrophic lateral sclerosis. Neurosci Lett 516:296\u2013301","journal-title":"Neurosci Lett"},{"key":"2048_CR54","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00109-015-1273-3","volume":"93","author":"J Hilton","year":"2015","unstructured":"Hilton J, White A, Crouch P (2015) Metal-deficient SOD1 in amyotrophic lateral sclerosis. J Mol Med 93:481\u2013487","journal-title":"J Mol Med"},{"key":"2048_CR55","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.chembiol.2018.05.004","volume":"25","author":"BG Trist","year":"2018","unstructured":"Trist BG, Hare DJ, Double KL (2018) A proposed mechanism for neurodegeneration in movement disorders characterized by metal dyshomeostasis and oxidative stress. Cell Chem Bio 25:807\u2013816","journal-title":"Cell Chem Bio"},{"key":"2048_CR56","doi-asserted-by":"publisher","first-page":"8021","DOI":"10.1523\/JNEUROSCI.4196-13.2014","volume":"34","author":"BR Roberts","year":"2014","unstructured":"Roberts BR et al (2014) Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a Transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 34:8021\u20138031","journal-title":"J Neurosci"},{"key":"2048_CR57","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nn1876","volume":"10","author":"M Nagai","year":"2007","unstructured":"Nagai M et al (2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10:615\u2013622","journal-title":"Nat Neurosci"},{"key":"2048_CR58","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0896-6273(00)80272-X","volume":"18","author":"LI Bruijn","year":"1997","unstructured":"Bruijn LI et al (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18:327\u2013338","journal-title":"Neuron"},{"key":"2048_CR59","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1039\/C6MT00099A","volume":"8","author":"J Hilton","year":"2016","unstructured":"Hilton J, White A, Crouch P (2016) Endogenous Cu in the central nervous system fails to satiate the elevated requirement for Cu in a mutant SOD1 mouse model of ALS. Metallomics 8:1002\u20131011","journal-title":"Metallomics"},{"key":"2048_CR60","doi-asserted-by":"publisher","first-page":"5929","DOI":"10.1038\/s41598-024-55832-w","volume":"14","author":"JBW Hilton","year":"2024","unstructured":"Hilton JBW et al (2024) Evidence for disrupted copper availability in human spinal cord supports Cu(II)(atsm) as a treatment option for sporadic cases of ALS. Sci Rep 14:5929","journal-title":"Sci Rep"},{"key":"2048_CR61","doi-asserted-by":"crossref","unstructured":"Zhang Z., et al. (2019). The Appropriate Marker for Astrocytes: Comparing the Distribution and Expression of Three Astrocytic Markers in Different Mouse Cerebral Regions. Biomed Res Int 9605265.","DOI":"10.1155\/2019\/9605265"},{"key":"2048_CR62","doi-asserted-by":"publisher","first-page":"E6496","DOI":"10.1073\/pnas.1607496113","volume":"113","author":"L Ferraiuolo","year":"2016","unstructured":"Ferraiuolo L et al (2016) Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc Natl Acad Sci U S A 113:E6496\u2013E6505","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2048_CR63","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1093\/brain\/awt097","volume":"136","author":"RA Saccon","year":"2013","unstructured":"Saccon RA, Bunton-Stasyshyn RK, Fisher EM, Fratta P (2013) Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 136:2342\u20132358","journal-title":"Brain"},{"key":"2048_CR64","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1093\/hmg\/ddq202","volume":"19","author":"S Pedrini","year":"2010","unstructured":"Pedrini S et al (2010) ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2. Hum Mol Genet 19:2974\u20132986","journal-title":"Hum Mol Genet"},{"key":"2048_CR65","doi-asserted-by":"publisher","first-page":"11588","DOI":"10.1523\/JNEUROSCI.5385-12.2013","volume":"33","author":"W Tan","year":"2013","unstructured":"Tan W et al (2013) Small peptides against the mutant SOD1\/Bcl-2 toxic mitochondrial complex restore mitochondrial function and cell viability in mutant SOD1-mediated ALS. J Neurosci 33:11588\u201311598","journal-title":"J Neurosci"},{"key":"2048_CR66","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3389\/fncel.2015.00336","volume":"9","author":"F Tafuri","year":"2015","unstructured":"Tafuri F, Ronchi D, Magri F, Comi GP, Corti S (2015) SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis. Front Cell Neurosci 9:336","journal-title":"Front Cell Neurosci"},{"key":"2048_CR67","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1212\/WNL.51.2_Suppl_2.S2","volume":"51","author":"O Hornykiewicz","year":"1998","unstructured":"Hornykiewicz O (1998) Biochemical aspects of parkinson\u2019s disease. Neurology 51:2\u20139","journal-title":"Neurology"},{"key":"2048_CR68","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0306-4522(91)90180-V","volume":"40","author":"M Herkenham","year":"1991","unstructured":"Herkenham M et al (1991) Selective retention of MPP\u2009+\u2009within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40:133\u2013158","journal-title":"Neuroscience"},{"key":"2048_CR69","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.1073\/pnas.0937239100","volume":"100","author":"DC Wu","year":"2003","unstructured":"Wu DC et al (2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinson\u2019s disease. Proc Natl Acad Sci U S A 100:6145\u20136150","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2048_CR70","doi-asserted-by":"crossref","unstructured":"An Y et al (2022) The role of copper homeostasis in brain disease. Int J Mol Sci 23","DOI":"10.3390\/ijms232213850"},{"key":"2048_CR71","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.freeradbiomed.2022.02.020","volume":"182","author":"Z Jiwaji","year":"2022","unstructured":"Jiwaji Z, Hardingham GE (2022) Good, bad, and neglectful: astrocyte changes in neurodegenerative disease. Free Radic Biol Med 182:93\u201399","journal-title":"Free Radic Biol Med"},{"key":"2048_CR72","doi-asserted-by":"crossref","unstructured":"Dennys CN et al (2022) CuATSM effectively ameliorates ALS patient astrocyte-mediated motor neuron toxicity in human in vitro models of amyotrophic lateral sclerosis. Glia, 1\u201316","DOI":"10.1002\/glia.24278"},{"key":"2048_CR73","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1474-4422(14)70129-2","volume":"13","author":"H Mitsumoto","year":"2014","unstructured":"Mitsumoto H, Brooks BR, Silani V (2014) Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 13:1127\u20131138","journal-title":"Lancet Neurol"},{"key":"2048_CR74","doi-asserted-by":"publisher","first-page":"102495","DOI":"10.1016\/j.eclinm.2024.102495","volume":"69","author":"M Wiesenfarth","year":"2024","unstructured":"Wiesenfarth M et al (2024) Effects of Tofersen treatment in patients with SOD1-ALS in a real-world setting - a 12-month multicenter cohort study from the German early access program. EClinicalMedicine 69:102495","journal-title":"EClinicalMedicine"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02048-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-025-02048-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-025-02048-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T15:01:47Z","timestamp":1750863707000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-025-02048-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2048"],"URL":"https:\/\/doi.org\/10.1186\/s40478-025-02048-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.02.26.640461","asserted-by":"object"}]},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures involving the use of mice conformed to the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, with protocols approved by the Animal Ethics Committee at the University of Sydney (Ethics ID: 2020\/1849).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript prior to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}